Early, Noninvasive Clinical Indicators of Kidney Prognosis in Primary Nephrotic Syndrome: A Retrospective Exploratory Study

Table 4

Univariate logistic regression analysis of predictive factors for intractable NS.

Clinical parameters		Odds ratio [95% CI]	value
At baseline
Age	Per 5 years of age	1.24 [0.95–1.62]	0.111
Sex	Male: 0, female: 1	0.92 [0.17–4.89]	0.925
Kidney tissue diagnosis	MCNS: 0, non-MCNS: 1	8.50 [0.90–80.03]	0.061
u-PCR	Per 1.0 g/gCr	0.91 [0.75–1.10]	0.327
Selectivity index	<0.2 : 0, ≥0.2 : 1	4.09 [0.67–24.83]	0.126
u-suPAR	Per 500 pg/mgCr	0.94 [0.75–1.19]	0.628
u-L-FABP	Per 1.0 μg/gCr	1.00 [0.99–1.01]	0.944
eGFR	Per 10 mL/min/1.73 m^2	0.87 [0.62–1.22]	0.422
s-Albumin	Per 1.0 g/dL	1.61 [0.26–9.90]	0.610
Total cholesterol	Per 10 mg/dL	0.95 [0.86–1.05]	0.286
s-suPAR	Per 500 pg/mL	1.16 [0.93–1.44]	0.199
Cyclosporine use in initial treatment	Nonuse: 0, use: 1	0.21 [0.03–1.33]	0.098
Change (Δ) within the first 2 months of IST
Δu-PCR (2M)	Per 1.0 g/gCr	1.32 [0.99–1.77]	0.063
Δu-suPAR (2M)	Per 500 pg/mgCr	1.36 [0.95–1.93]	0.093
Δu-L-FABP (2M)	Per 1.0 μg/gCr	1.00 [0.99–1.01]	0.809
ΔeGFR (2M)	Per 10 mL/min/1.73 m^2	0.77 [0.43–1.40]	0.397
Δs-suPAR (2M)	Per 500 pg/mL	2.40 [1.15–5.03]	0.020
At 2 months after initiating IST
u-PCR (2M)	Per 1.0 g/gCr	7.87 [2.02–30.73]	0.003
u-suPAR (2M)	Per 500 pg/mgCr	1.14 [0.92–1.42]	0.238
u-L-FABP (2M)	Per 1.0 μg/gCr	1.14 [1.01–1.29]	0.038
eGFR (2M)	Per 10 mL/min/1.73 m^2	0.74 [0.50–1.11]	0.149
s-suPAR (2M)	Per 500 pg/mL	1.44 [1.01–2.04]	0.041

MCNS, minimal-change nephrotic syndrome; s-, serum; u-, urinary; PCR, protein-to-creatinine ratio; suPAR, soluble urokinase plasminogen activator receptor; L-FABP, liver-type fatty acid-binding protein; eGFR, estimated glomerular filtration rate; IST, immunosuppressive therapy.